Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities

摘要

The use of cannabidiol (CBD) for the treatment of epileptic seizures associated with rare epilepsy syndromes, the seizures treated are in patients diagnosed with a B-RAF mutation. In a further embodiment the types of seizures include tonic-clonic seizures. Preferably the CBD comprises greater than 98% (w/w) CBD and less than or equal to 2% (w/w) of other cannabinoids. Where the CBD is given concomitantly with one or more other anti-epileptic drugs (AED) including valproic acid, levetiracetam, clobazam, lacosamide, N-desmethylclobazam and clorazepate. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day. Preferably the CBD used is in the form of a botanically derived purified CBD, but a synthetically produced CBD can alternatively be used.